Where AI Belongs in IRB Review, and Where It Doesn’t
Advarra’s position on AI in IRB review: what the board will always decide, where AI can fit in IRB operations,
Advarra’s position on AI in IRB review: what the board will always decide, where AI can fit in IRB operations,
Aligning Institutional Policy With System Updates: A Practical Guide Keep institutional policies, research administration workflows, and technology aligned as your
Adaptive study designs are best suited for oncology clinical trials when meaningful uncertainty exists and a protocol can prospectively use
Clinical trial audits are independent quality assurance evaluations of trial activities, records, systems, facilities, and organizations. The main types include:
Investigator-initiated trials (IITs) play a critical role in advancing clinical research by allowing investigators to pursue important scientific questions beyond
The U.S. Office of Information and Regulatory Affairs (OIRA), within the Office of Management and Budget (OMB), released the federal
Planned changes outlined in the U.S. federal government’s 2026 Regulatory Plan and the Unified Agenda of Federal Regulatory and Deregulatory
On July 3, 2026, the U.S. Office of Information and Regulatory Affairs (OIRA), within the Office of Management and Budget
With all the buzz recently on regulatory reform for institutional review boards (IRBs), it’s worth looking back to the foundation
Researchers often want to know early whether a study will be considered Not Human Subjects Research (NHSR), exempt, eligible for
Clinical research decisions are only as sound as the records supporting them, and that soundness begins with data integrity: the
Determining whether an event requires prompt institutional review board (IRB) reporting is an important part of protecting research participants, supporting effective